Showing results (491-500 of 601) with videos related to
Sort By:
Pageof 61
The New England Journal of Medicine|January 22, 2010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosisJeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, et al.CPT: Pharmacometrics & Systems Pharmacology|June 4, 2021
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathyMichael A Tortorici, Theresa Yuraszeck, David Cornblath, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2025
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trialsJeffrey A Cohen, Douglas L Arnold, John DeLuca, et al.International Journal of Molecular Sciences|June 24, 2020
Secretome Analysis of Mesenchymal Stem Cell Factors Fostering Oligodendroglial Differentiation of Neural Stem Cells In VivoIria Samper Agrelo, Jessica Schira-Heinen, Felix Beyer, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.Archives of Neurology|September 12, 2007
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsFrederik Barkhof, Chris H Polman, Ernst-Wilhelm Radue, et al.The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.Frontiers in Neurology|March 19, 2019
An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune EncephalitisElsie Amedonu, Christoph Brenker, Sumanta Barman, et al.Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.Neurology|May 31, 2015
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSLudwig Kappos, Ernst-Wilhelm Radue, Giancarlo Comi, et al.Pageof 61